BeBetter Med, based in China, is an NDA-stage R&D company with seven clinical assets. Its US subsidiary, BeBetter Pharma, focuses on next-gen siRNA therapeutics, using proprietary platforms, Peptide-Oligonucleotide Conjugates (POCs) and GalNAc Dual Oligonucleotide Conjugates (GDOCs), with multiple preclinical programs.

BeBetter Med and its subsidiary, BeBetter Pharma, are dedicated to forging strategic international collaborations to accelerate the development and commercialization of their innovative therapeutic programs. BeBetter Med focuses on partnering with experts in small molecule drug development and commercialization, while BeBetter Pharma seeks collaborations with leaders in RNA therapeutics. By leveraging its proprietary siRNA delivery platforms (POCs and GDOCs), BeBetter Pharma aims to address unmet medical needs in preclinical and early-stage programs. Together, both entities prioritize partnerships that enhance their R&D capabilities, broaden global reach, and drive value through co-development, licensing, and joint venture opportunities.